Mounjaro and Heart Attacks: What the Clinical Evidence Shows

What the SURMOUNT trials found about heart and metabolic risk

The SURMOUNT-1 trial, published in the New England Journal of Medicine, enrolled 2,539 adults with obesity and demonstrated average body-weight reductions of around 20% at the highest dose over 72 weeks. That matters cardiovascularly because excess weight is a primary driver of the conditions that raise heart attack risk: hypertension, dyslipidaemia, insulin resistance and systemic inflammation. Across the SURMOUNT programme, tirzepatide consistently reduced waist circumference, blood pressure and HbA1c. None of those are soft surrogates; each is a recognised cardiovascular risk factor under UK clinical guidelines.

The trial populations were not primarily selected for existing heart disease, so the data does not directly answer what happens in people who have already had a myocardial infarction. That distinction matters. Reduced risk factors are not the same as a proven reduction in major cardiac events, and it would be inaccurate to claim otherwise.

The NICE technology appraisal TA1026 for tirzepatide acknowledged the cardiovascular risk-factor improvements in its clinical assessment, and the committee noted that indirect comparisons with semaglutide were broadly favourable. Cardiovascular outcomes data, though, was flagged as an area where the evidence base would continue to develop.

How tirzepatide's mechanism relates to heart attack risk

Tirzepatide acts on both the GIP and GLP-1 receptors, making it the only dual-agonist weight-loss medicine licensed in the UK. GLP-1 receptor agonists as a class have been studied for cardiovascular effects for over a decade, partly because GLP-1 receptors are expressed in cardiac tissue. The GLP-1 medicine semaglutide demonstrated a significant reduction in major adverse cardiovascular events in the SELECT trial, which enrolled adults with established cardiovascular disease and obesity but without diabetes. That was a dedicated outcomes trial with tens of thousands of participants.

Tirzepatide does not yet have equivalent completed outcomes data, but SURPASS-CVOT is running that study. In the meantime, the metabolic profile tirzepatide produces is one that cardiologists generally consider favourable, and anyone wanting a fuller picture can read our dedicated page on Mounjaro and heart disease, which goes into the SELECT comparison in more detail.

One practical note for people on heart medications: tirzepatide slows gastric emptying, which can transiently affect the absorption of other orally taken medicines. If you take rate-controlling drugs or anticoagulants, that conversation belongs with your prescriber before you start, not after.

When heart attack history changes the clinical picture

Having had a heart attack does not automatically disqualify someone from tirzepatide, but it does change what the prescriber needs to know. The SmPC lists no absolute contraindication specific to ischaemic heart disease, but clinical judgement governs which medicines are safe in combination with the other treatments a cardiac patient typically takes. A previous myocardial infarction also often means a patient is on beta-blockers, ACE inhibitors, statins and antiplatelets simultaneously.

Our prescribers review the whole clinical picture, not just BMI. If you have a cardiac history, they will ask about it; that is not a barrier to applying, it is part of a thorough assessment. You can find out what that consultation involves via our frequently asked questions.

It is also worth knowing what symptoms should prompt urgent attention whilst on any GLP-1 medicine. Chest pain, pain radiating to the arm or jaw, sudden breathlessness and severe dizziness are signs to call 999, not to self-manage or assume the medication is responsible. Tell the treating team what you are taking. If you want a detailed look at whether Mounjaro can cause a heart attack, including what the current evidence says and when to seek advice, we cover that question directly in a dedicated page.

Heart rate changes: a separate but related question

A question that comes up alongside the heart attack topic is whether tirzepatide raises heart rate. GLP-1 receptor agonists are known to produce a modest increase in resting heart rate in some people, typically a few beats per minute. This is generally benign, but it is relevant for anyone with pre-existing arrhythmia or conditions where heart rate is tightly managed. The evidence so far does not suggest tirzepatide produces clinically significant tachycardia in otherwise healthy adults, but it is another reason cardiac context belongs in the consultation. Our dedicated page on tirzepatide and heart rate changes goes through what the data shows.

If cost is part of your thinking about private treatment, our tirzepatide cost page sets out what is typically included in a private prescription service and what the market context looks like since the Eli Lilly price changes in 2025. Worth a read before drawing conclusions from a headline figure.

For anyone ready to explore whether tirzepatide is clinically suitable for them, including those with cardiovascular history, speaking to our prescribers is the first step. Consultations are reviewed the same day by a named, GPhC-registered Independent Prescriber, not by an automated system, and cardiac history is taken seriously from the outset. Patients who have read our reviews from people who have tried Mounjaro often find it helpful to hear how others with complex health backgrounds approached starting treatment.